Further supporting this hypothesis in the case of KAT2A is the observation that KAT2A-targeting shRNAs were specifically depleted (t test p = 0.06) in terms of incorporation into prostate cancer cell lines relative to all other cancer cell lines in the Achilles high-throughput screen [32]. The gene discussed is KAT2A; the disease is prostate carcinoma.